By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Contraceptives > Ethinyl estradiol and ethynodiol diacetate > Ethinyl Estradiol / Ethynodiol Dosage
Contraceptives
https://themeditary.com/dosage-information/ethinyl-estradiol-ethynodiol-dosage-11229.html

Ethinyl Estradiol / Ethynodiol Dosage

Drug Detail:Ethinyl estradiol and ethynodiol diacetate (Ethinyl estradiol and ethynodiol diacetate [ eth-in-ill-ess-tra-dye-ol-and-eth-in-o-dye-ol-dye-as-e-tate ])

Drug Class: Contraceptives

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Contraception

Ethinyl estradiol-ethynodiol products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert.

1 tablet orally at the same time once a day

  • Begin on the first day of menstrual period (Day 1 start)

If the start date of the initial cycle is any day other than the first day of the menstrual cycle, this drug should not be considered effective as a contraceptive until after the first 7 consecutive days of administration have been completed; a non-hormonal contraceptive should be used as back-up during these first 7 days

Comments:
  • This drug should be taken in the order directed on the package at the same time each day
  • The possibility of ovulation and conception prior to initiation should be considered.

Use: This drug is indicated in women to prevent pregnancy.

Usual Pediatric Dose for Contraception

Ethinyl estradiol-ethynodiol products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert.

Postpubertal adolescents:
1 tablet orally at the same time once a day

  • Begin on the first day of menstrual period (Day 1 start)

If the start date of the initial cycle is any day other than the first day of the menstrual cycle, this drug should not be considered effective as a contraceptive until after the first 7 consecutive days of administration have been completed; a non-hormonal contraceptive should be used as back-up during these first 7 days

Comments:
  • This drug should be taken in the order directed on the package at the same time each day
  • The possibility of ovulation and conception prior to initiation should be considered.

Use: This drug is indicated in women to prevent pregnancy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:

  • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age and with heavy smoking (15 or more cigarettes/day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

CONTRAINDICATIONS:
  • Thrombophlebitis or thromboembolic disorders
  • History of deep vein thrombophlebitis or thromboembolic disorders
  • Current or history or cerebral vascular disease, myocardial infarction, or coronary artery disease
  • Known, suspected, or history of breast cancer
  • Known, suspected, or history of cancer of the female reproductive organs or estrogen-dependent neoplasia
  • Undiagnosed abnormal uterine bleeding
  • History of cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use
  • Liver tumors, benign or malignant
  • Pregnancy
  • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations

Safety and efficacy have been established in female patients of reproductive age; use prior to menarche is not indicated.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally once a day at the same time every day

Missed Doses:
  • If 1 active tablet is missed: Take the missed dose as soon as possible and continue taking 1 tablet once a day until packet is finished
  • If 2 active tablets are missed in a row in Week 1 or Week 2: Take 2 tablets on the day remembered and 2 tablets the next day, then 1 tablet once a day until pack is finished; ADDITIONALLY, non-hormonal contraception (e.g. condoms or spermicide) must be used as back-up for intercourse within 7-days after missing tablets
  • If 2 active tablets are missed in a row in Week 3: For day 1 starters (started on day 1 of menstrual period); Throw out rest of the pack and start a new pack; For Sunday starters (started on Sunday after menstrual period): Continue taking 1 pill every day until Sunday, on Sunday, start a new pack; ADDITIONALLY, non-hormonal contraception (e.g. condoms or spermicide) must be used as back-up for intercourse within 7-days after restarting. A woman may miss her period this month, but if a period is missed for 2 months in a row, pregnancy should be ruled out.
  • If 3 active tablets are missed in a row in any week: For day 1 starters (started on day 1 of menstrual period); Throw out rest of the pack and start a new pack; For Sunday starters (started on Sunday after menstrual period): Continue taking 1 pill every day until Sunday, on Sunday, start a new pack; ADDITIONALLY, non-hormonal contraception (e.g. condoms or spermicide) must be used as back-up for intercourse within 7-days after restarting. A woman may miss her period this month, but if a period is missed for 2 months in a row, pregnancy should be ruled out.

General:
  • COCs may cause fluid retention; prescribe with caution and careful monitoring in patients with conditions that might be aggravated by fluid retention such as convulsive disorders, migraine syndrome, asthma, or cardiac, hepatic, or renal dysfunction.
  • Women who take oral contraceptives, should take the lowest possible dose formulation that is effective.

Monitoring:
  • Monitor blood pressure
  • Patients with diabetes may require additional glycemic monitoring
  • Observe patients with history of depression for recurrence or worsening depression

Patient advice:
  • Patients should be instructed to read the US FDA-approved patient labeling.
  • Patients should be informed that there are drug interactions with this drug and they should discuss all medications they are taking, including herbal supplements with their healthcare provider.
  • Patients should be instructed to seek medical help promptly if they experience signs or symptoms of blood clots.
  • Patients should understand that oral contraceptive medications do not protect against HIV-infection and other sexually transmitted infections.
  • For contact lens wearers who notice a change in vision or an inability to wear contact lenses, they should contact their ophthalmologist.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by